(July 27, 2020) Research from the Ovarian Cancer Association Consortium (OCAC) found that “using menopausal hormone therapy prior to diagnosis extends ovarian cancer survival.” This was found through a comprehensive analysis involving 6,419 post-menopausal women with ovarian carcinoma. Study authors concluded, “This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.”
Three members of OCRA’s Scientific Advisory Committee are listed as contributors to this work: Andrew Berchuck, MD, Ellen Goode, PhD, and Celeste Leigh Pearce, PhD, MPH.
To read more about this study, access the publication through Science Direct.
OCAC has been funded by the Ovarian Cancer Research Fund (OCRF), which merged in 2016 with the Ovarian Cancer National Alliance (OCNA) to become OCRA.
